HalioDx SAS, an immuno-oncology diagnostic company, today announced that Gencell Pharma will market and distribute Immunoscore® Colon assay in Colombia.
Oncologists and patients in Colombia will have access to Immunoscore® Colon, a unique diagnostic assay that predicts the risk of recurrence of patients with early stage colon cancer. The assay guides oncologists to decide on critical therapeutic options in stage II and stage III colon cancers. Immunoscore® Colon combines tissue diagnostic and advanced image analysis technologies to quantify T-cells which infiltrate both the core of the colon tumor and its invasive margin. It is the very first IVD assay of the HalioDx Immunoscore® pipeline, leveraging image analysis technology to enhance clinical utility and standardization.
Immunoscore® Colon will be marketed in Colombia by Gencell Pharma leveraging their expertise in offering innovative testing solutions to physicians and patients.
“Colorectal cancer is the first most prevalent malignant disease in Colombia. According to Globocan 2012 there were 14 105 new cases of Colorectal cancer of which ~ 9 870 are Colon cancer. We estimate that for approximately half of these cases the access to Immunoscore® Colon will enable physicians to assess better Colon cancer recurrence risk and adjust therapeutic options accordingly. We are excited to add Immunoscore® Colon to our portfolio of testing services in Colombia and proud to introduce this important test to the Colombia market”, noted Andres Zapata, CEO of Gencell Pharma.
“We are delighted to collaborate with Gencell Pharma, an expert company enabling Colombian oncologists and patients to access value-based diagnostic solutions,” added Vincent Fert CEO of HalioDx.
Immunoscore® Colon was discovered by Dr. Jérôme Galon and developed in compliance with the IVD standards by HalioDx. The clinical value has been validated in several studies on early stage colon cancer patients. Recently the results of the SITC International study conducted on more than 2600 patients have been published in The Lancet journal. The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N0147 study.